Immune-based therapy successful in a third of cervical pre-cancers

Organisation: Position: Deadline Date: Location:

A potential new immune-based therapy to treat pre-cancers in the cervix completely eliminated both the lesion and the underlying HPV infection in a third of women enrolled in a clinical trial. The shot, a therapeutic vaccine, injects a specific protein that triggers an immune system response to attack high-risk HPV types that cause nearly all cervical cancer precursors, known as cervical intraepithelial neoplasia (CIN).

“There are very few products trying to cure women who already have an HPV infection,” says Dr Diane Harper, professor of family medicine and obstetrics and gynaecology at Michigan Medicine. “It’s very exciting. This is the first time we’ve seen something with this success rate that is relatively easy to implement.”

Cervical precancerous lesions are divided into three grades of severity: CIN 1 lesions generally clear up on their own. CIN 2 lesions often clear up on their own, but can also progress to CIN 3 lesions. CIN 3 is the most severe. It’s a very slow-growing disease, though: fewer than half of CIN 3 lesions will have become cancer within 30 years.

“But we have no way to determine which women with CIN 3 will progress to cancer and which women will not. So, we treat all women with CIN 2 or 3 as if they are likely to develop cancer,” Harper says.

The study enrolled 192 women diagnosed with CIN2 or CIN3, randomising 129 to receive the vaccine and 63 to receive a placebo. Women were given three shots in their thigh, one per week for three weeks. Six months later, the women were treated with standard surgical procedures for CIN 2/3 and the removed tissue was examined.

Women who received the vaccine were more than twice as likely as those who received placebo to see their CIN eliminated regardless of the type of HPV infection. The results were most striking in the more-severe CIN3: at least 15% and as much as 36% of those who got the vaccine saw their CIN3 eliminated, while none of the women in the placebo group did.

Researchers followed the participants for another two and a half years after surgery, the longest any study has followed women in these trials. They showed that long-term follow-up was better for those who received vaccine over placebo, with more women in the vaccine group remaining completely clear of HPV.

Harper notes that the therapeutic vaccine, called Tipapkinogen Sovacivec, or TS, is completely different from Gardasil9, the vaccine given to prevent HPV infection. While Gardasil9 prevents HPV infection from occurring, TS clears tissue already infected with HPV. CIN2 and CIN3 are always caused by high-risk HPV infections.

The typical treatment procedure for CIN2 or CIN3 involves removing a cone-shaped piece of the cervix, called a LEEP or a cone. This results in scarring and a shortened cervix, which can cause problems during childbirth and lead to increased risk of caesarean section. In addition, women who have this procedure have a very high risk of developing cervical cancer over the next 20 years if they do not continue to be screened.

“The surgical procedure removes all the tissue that is headed towards cancer, but it doesn’t remove all the HPV. You’re not home-free. You still have HPV,” says Harper, an internationally recognised HPV researcher and member of the University of Michigan Rogel Cancer Centre and senior associate director of the Michigan Institute of Clinical and Health Research (MICHR).

With the vaccine, researchers found that it not only eliminated the lesions but also eliminated the HPV infection. “It actually treats the cause of the disease, which is HPV,” Harper says.

Women who received the vaccine injections reported sometimes-severe reactions at the injection site. Harper says that was expected, because the vaccine is designed to trigger the immune system. An immune reaction is likely to inflame the skin.

The study looked only at cervical lesions, but HPV is linked to several other types of cancer, including head and neck cancer and anal cancer. The researchers envision testing TS for these cancers in the future. Additional clinical trials are needed before seeking approval for TS from the US Food and Drug Administration. No trials are currently available.

Abstract
Background: While prophylactic human papillomavirus (HPV) vaccination exists, women are still developing cervical intraepithelial neoplasia (CIN) grade 2 or 3 for which an immunotherapeutic, non-surgical, approach may be effective. The primary aim was to assess the efficacy of tipapkinogen sovacivec (TS) vaccine in achieving histologic resolution of CIN2/3 associated with high risk (HR) HPV types.
Methods: Women 18 years and older who had confirmed CIN2/3 were enrolled in a randomized, double blind, placebo-controlled phase II trial and assigned to drug in a 2:1 ratio (vaccine:placebo). The primary endpoint occurred at month 6 when the excisional therapy was performed; cytology and HR HPV typing were performed at months 3, 6 and every six months through month 30. The safety population included all patients who received at least one dose of study drug.
Results: Of the 129 women randomized to vaccine and 63 to placebo, complete resolution was significantly higher in the vaccine group than placebo for CIN 2/3 regardless of the 13 HR HPV types assayed (24% vs. 10%, p < 0.05); as well as for only CIN 3 also regardless of HR HPV type (21% vs. 0%, p < 0.01). Irrespective of baseline HPV infection, viral DNA clearance was higher in the vaccine group compared to placebo (p < 0.01). The vaccine was well tolerated with the most common adverse events being injection site reactions.
Conclusions: The TS vaccine provides histologic clearance of CIN 2/3 irrespective of HR HPV type in one third of subjects and is generally safe through 30 months.

Authors
Diane M Harper, Pekka Nieminen, Gilbert Donders, Mark H Einstein, Francisco Garcia, Warner K Huh, Mark H Stoler, Katerina Glavini, Gemma Attley, Jean-Marc Limacher, Berangere Bastien, Elizabeth Calleja

Michigan Medicine – University of Michigan material
Gynecologic Oncology abstract


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.